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Dear Editor,
We have read with great interest the meta-analysis by Yang et al. (1). The reported objective was to evaluate the relation between cytokeratin-18 (CK-18) levels and hepatitis pathogenesis. Eight case-control studies were included in the meta-analysis according to the selection criteria adopted. High serum CK-18 levels were found in patients with hepatitis compared to controls. Moreover, increased serum CK-18 levels were related to fibrosis pro-gression irrespective of ethnicity (Asians, Africans, and Caucasians) and liver disease etiology (chronic hepatitis C, chronic hepatitis B, and nonalcoholic steatohepatitis [NASH]). The authors concluded that serum CK-18 could be adopted as a diagnostic marker of liver injury and as a predictor of hepatitis progression (1).Although the authors correctly reported the presence of several specific limitations, it should be highlighted that the pathogenetic mechanism leading to liver dam-age and fibrogenesis varies according to the underlying liver disease etiology. CK-18 is a serological marker of apoptosis. Although circulating levels of CK-18 have been shown to be elevated in different liver disorders (2, 3), hepatocyte apoptosis seems to play a critical role in liver injury only in the setting of nonalcoholic fatty liver dis-ease (NAFLD) to NASH evolution (4). Moreover, the clini-cal value of CK-18 for NASH diagnosis and fibrosis severity prediction has been recently questioned in a study ex-amining CK-18 relationship with clinical/metabolic and histologic parameters in a large multiethnic NAFLD pop-ulation. In this study, not included in the meta-analysis, CK-18 showed just a modest correlation with the severity of fibrosis (r =0.32) and lobular inflammation (r =0.28). In 
addition, the performance for NASH and fibrosis diagno-sis was poor as reflected by values of area under the curve (AUC) of 0.65, sensitivity (Se) of 58%, and negative predic-tive value (NPV) of 49% and AUC of 0.68, Se of 54%, and NPV of 56%, respectively (5).In conclusion, CK-18 diagnostic value in distinguish-ing NAFLD from NASH has been currently reconsidered. Further studies are required to explore the possible use of CK-18 in combination with other noninvasive markers of fibrosis to achieve a more accurate diagnosis of NASH and fibrosis severity.
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